VCAN and neoplasm: However, an N-terminal proteolytic fragment of VCAN, versikine, arising through the actions of ADAMTS-4 and other versicanases, conversely regulates cross-presenting type 1 conventional dendritic cell (cDC1) abundance and activation in the TME, to promote immune cell trafficking to the tumor and effector priming [41].